ProQR (PRQR) has released an update.
ProQR Therapeutics reports a notable increase in revenue for the first nine months of 2024, climbing to €14.6 million from €3.2 million in the previous year, despite incurring higher operating costs. The company’s total assets have decreased from €137.9 million to €106.9 million over the same period, reflecting changes in cash reserves and liabilities. This financial update highlights both growth in revenue and strategic challenges as ProQR navigates its financial landscape.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.
